<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) <z:hpo ids='HP_0011420'>deaths</z:hpo> in the PLATO (Platelet Inhibition and Patient Outcomes) trial </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: In the PLATO trial, patients assigned to ticagrelor compared with <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> and who underwent CABG had significantly lower total and cardiovascular mortality </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatment assignment classified causes of <z:hpo ids='HP_0011420'>death</z:hpo> into subcategories of vascular and nonvascular, and specifically identified <z:mp ids='MP_0001914'>bleeding</z:mp> or <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> events that either caused or subsequently contributed to <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Numerically more vascular <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred in the <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> versus the ticagrelor group related to <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (14 vs. 10), <z:hpo ids='HP_0001635'>heart failure</z:hpo> (9 vs. 6), <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> or <z:hpo ids='HP_0001699'>sudden death</z:hpo> (9 vs. 3), and <z:mp ids='MP_0001914'>bleeding</z:mp>, including hemorrhagic <z:hpo ids='HP_0001297'>stroke</z:hpo> (7 vs. 2) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> was also associated with an excess of nonvascular <z:hpo ids='HP_0011420'>deaths</z:hpo> related to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (8 vs. 2) </plain></SENT>
<SENT sid="5" pm="."><plain>Among factors directly causing or contributing to <z:hpo ids='HP_0011420'>death</z:hpo>, <z:mp ids='MP_0001914'>bleeding</z:mp> and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were more common in the <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> group compared with the ticagrelor group (<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>: 16 vs. 6, p &lt; 0.05, and <z:mp ids='MP_0001914'>bleeding</z:mp>: 27 vs. 9, p &lt; 0.01, for <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> and ticagrelor, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The mortality reduction with ticagrelor versus <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> following CABG in the PLATO trial was associated with fewer <z:hpo ids='HP_0011420'>deaths</z:hpo> from cardiovascular, <z:mp ids='MP_0001914'>bleeding</z:mp>, and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> complications </plain></SENT>
<SENT sid="7" pm="."><plain>(Platelet Inhibition and Patient Outcomes [PLATO]; NCT00391872) </plain></SENT>
</text></document>